Biopharma venture capital activity in the fourth quarter of 2023 saw a downturn, capping off a disappointing year for sector funding as a whole, according to a new report from market data firm Pitchbook.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,